选择性内乳淋巴结照射对淋巴结阳性乳腺癌无病生存的影响:随机3期临床试验
该多中心3期随机试验纳入735例淋巴结阳性乳腺癌患者,比较区域淋巴结照射联合或不联合内乳淋巴结照射(IMNI)的疗效。7年无病生存率无显著差异(81.9% vs 85.3%;HR 0.80;95%CI 0.57-1.14;P=0.22),但中央/内侧肿瘤亚组接受IMNI者无病生存率显著更高(91.8% vs 81.6%;HR 0.42;95%CI 0.22-0.82;两组不良反应无差异。
要点
- 总体人群加用IMNI未显著改善7年无病生存。
- 中央/内侧肿瘤亚组加用IMNI与更高无病生存相关。
- 两组心脏毒性及放射性肺炎发生率无差异。
核心结论
- 在淋巴结阳性乳腺癌中,区域淋巴结照射加用IMNI未显著改善总体7年无病生存。
- 中央或内侧肿瘤患者可能从IMNI中获益。
研究设计与样本
- 多中心3期随机临床试验,2008年6月1日至2020年2月29日在韩国13家医院开展。
- 纳入735例病理确诊淋巴结阳性乳腺癌患者,均接受区域淋巴结照射及乳腺/胸壁照射,1:1随机加或不加IMNI。
- 主要终点为7年无病生存,按意向治疗原则分析。
主要发现
- 7年无病生存率:不加IMNI组81.9% vs 加IMNI组85.3%(HR 0.80;95%CI 0.57-1.14;log-rank P=0.22)。
- 两组不良反应(包括心脏毒性和放射性肺炎)发生率无差异。
临床怎么用
- 淋巴结阳性乳腺癌区域淋巴结照射常规不加IMNI,总体无病生存无显著获益。
- 对中央或内侧肿瘤患者,可考虑加用IMNI以改善无病生存。
局限性
- 中央/内侧肿瘤亚组分析为事后分析(ad hoc),需谨慎解读。
- 随访时间中位数约100.4个月,长期安全性数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The benefit of internal mammary node irradiation (IMNI) for treatment outcomes in node-positive breast cancer is unknown. OBJECTIVE: To investigate whether the inclusion of IMNI in regional nodal irradiation improves disease-free survival (DFS) in women with node-positive breast cancer. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, phase 3 randomized clinical trial was conducted from June 1, 2008, to February 29, 2020, at 13 hospitals in South Korea. Women with pathologically confirmed, node-positive breast cancer after breast-conservation surgery or mastectomy with axillary lymph node dissection were eligible and enrolled between November 19, 2008, and January 14, 2013. Patients with distant metastasis and those who had received neoadjuvant treatment were excluded. Data analyses were performed according to the intention-to-treat principle. INTERVENTIONS: All patients underwent regional nodal irradiation along with breast or chest wall irradiation. They were randomized 1:1 to receive radiotherapy either with IMNI or without IMNI. MAIN OUTCOMES AND MEASURES: The primary end point was the 7-year DFS. Secondary end points included the rates of overall survival, breast cancer-specific survival, and toxic effects. RESULTS: A total of 735 women (mean [SD] age, 49.0 [9.1] years) were included in the analyses, of whom 373 received regional nodal irradiation without IMNI and 362 received regional nodal irradiation with IMNI. Nearly all patients underwent taxane-based adjuvant systemic treatment. The median (IQR) follow-up was 100.4 (89.7-112.1) months. The 7-year DFS rates did not significantly differ between the groups treated without IMNI and with IMNI (81.9% vs 85.3%; hazard ratio [HR], 0.80; 95% CI, 0.57-1.14; log-rank P = .22). However, an ad hoc subgroup analysis showed significantly higher DFS rates with IMNI among patients with mediocentrally located tumors. In this subgroup, the 7-year DFS rates were 81.6% without IMNI vs 91.8% with IMNI (HR, 0.42; 95% CI, 0.22-0.82; log-rank P = .008), and the 7-year breast cancer mortality rates were 10.2% without IMNI vs 4.9% with IMNI (HR, 0.41; 95% CI, 0.17-0.99; log-rank P = .04). No differences were found between the 2 groups in the incidence of adverse effects, including cardiac toxic effects and radiation pneumonitis. CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that including IMNI in regional nodal irradiation did not significantly improve the DFS in patients with node-positive breast cancer. However, patients with medially or centrally located tumors may benefit from the use of IMNI. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04803266.
引用
- Kim YB, Byun HK, Kim DY, et al. Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial. JAMA Oncol. 2022. PMID: 34695841. doi:10.1001/jamaoncol.2021.6036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。